Shots: 

• The EC has approved Afqlir(2mg vial kit & pre-filled syringe for intravitreal injection), biosimilar of Bayer’s Eylea (aflibercept), with the launch anticipated in Q4’25  

• Afqlir's biosimilar development program included analytical, preclinical & clinical data from the Mylight trial, establishing its equivalence in terms of efficacy & safety to the reference medicine 

• Aflibercept is a recombinant fusion protein that inhibits abnormal vessel growth by binding with VEGF-A & placental growth factor (PlGF), enhancing visual acuity & inhibiting disease progression 

Ref: Sandoz | Image: Sandoz

Related News:- Sandoz Reports the US FDA’s Approval of Enzeevu (Biosimilar, Eylea) to Treat Neovascular Age-Related Macular Degeneration

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com